Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

REMEVi vs ShedRx

Two GLP-1 desks, one scoreboard. We put REMEVi and ShedRx head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 12 · Grade B+

REMEVi

Visit REMEVi Full brief →
vs
No. 5 · Grade B+

ShedRx

Visit ShedRx Full brief →

The verdict

Too close to call on the Brief Score.

REMEVi and ShedRx are level at 87/100. The scores won't separate them, so the pick comes down to fit: REMEVi for readers who want spanish-speaking patients wanting bilingual, legitscript-certified compounded glp-1. ShedRx for readers who want an oral or sublingual option, or one of the lower tirzepatide prices on the tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
78
86
Supply Reliability
88
86
Transparency
88
84
Access Breadth
96
85
Clinical Oversight
87
85
Track Record
87
86
REMEViBrief Score 87 · 87ShedRx

Price, coverage & the tracker

REMEViShedRx
Brief Score87/100 (B+)87/100 (B+)
Semaglutide$219/mo (all doses, compounded)$199/mo
Tirzepatide$319/mo (all doses, compounded)$299/mo
CoverageAll 50 statesNot disclosed
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesYes
On the trackerNewnew to the tracker, no prior readingFallingprice falling

REMEVi: New to the tracker on 1 August 2026, and read on the provider's own site rather than taken on trust: we checked https://remevihealth.com/pricing on 2026-08-01 and this row reflects what that page says. The line we publish is $219/mo (all doses, compounded). There is no earlier reading of ours to compare it against yet.

ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.

Not sold on either?

CoreAge Rx tops the whole ranking at 94/100.

The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.